Core Insights - EssilorLuxottica's Essilor Stellest lens is the first FDA market authorized spectacle lens in the U.S. that is clinically proven to slow myopia progression in children [1][2] - The lens has shown an average reduction of 71% in myopia progression over two years in clinical trials [1][5] - The company aims to address the global myopia epidemic, with plans to make the lens available to U.S. eyecare professionals shortly [1][3] Company Developments - EssilorLuxottica has been conducting research in myopia for over four decades, leading to the launch of the Essilor Stellest lens, which is now used by millions of children globally [3] - The lens represents a significant advancement in vision care, evolving traditional corrective lenses into a medical treatment for myopia [2][3] - The FDA's market authorization is seen as a major milestone for the company in its mission to enhance eye health and empower individuals [2] Industry Context - The myopia epidemic is projected to affect half of the global population by 2050, with 740 million children potentially impacted [4] - In North America, over 40% of adults and 25% of children aged 6 to 19 are affected by myopia, with increasing prevalence noted in recent studies [4]